Can-Fite Reports Longer Overall Survival in Phase III Liver Cancer Study
RAMAT GAN, Israel, September 2, 2026 Can-Fite BioPharma Ltd. reported that blinded overall survival observed across the entire patient...
overall survival
Advertisement
Jazz Reports Survival Benefit for Ziihera in GEA
Dublin, Ireland, August 31, 2026 Jazz Pharmaceuticals plc announced positive topline results from the Phase 3 HERIZON-GEA-01 clinical trial,...
HUTCHMED Reports Phase III SANOVO PFS Benefit in EGFR NSCLC
Hong Kong, Shanghai & Florham Park, NJ – August 31, 2026 HUTCHMED (China) Limited announced positive high-level results from...
Agenus Reports Durable BOT+BAL Activity in MSS Colorectal Cancer
Lexington, Mass. – August 28, 2026 Agenus Inc. announced the publication of mature Phase 1b results evaluating botensilimab (BOT)...
AstraZeneca Discontinues eVOLVE-Lung02 Phase 3 Trial
Cambridge, UK — August 17, 2026 AstraZeneca announced that it is discontinuing the eVOLVE-Lung02 Phase III trial evaluating volrustomig...
Advertisements
AIM ImmunoTech Advances Ampligen Toward Phase 3 Cancer Trial
OCALA, Fla., August 10, 2026 AIM ImmunoTech Inc. reported its second-quarter 2026 financial results and highlighted continued progress in...
CervoMed Secures UK ILAP Innovation Passport for Neflamapimod
BOSTON, Aug. 4, 2026 CervoMed Inc. announced that its investigational oral therapy neflamapimod has been granted an Innovation Passport...
AIM ImmunoTech Advances DURIPANC Trial with Final Dosing Milestone
OCALA, Fla., Aug. 3, 2026 AIM ImmunoTech Inc. announced that the final patient has received the last protocol-defined dose...
Daiichi Sankyo and AstraZeneca Receive EU Approval for Datroway in First-Line Metastatic TNBC
TOKYO, July 31, 2026 Daiichi Sankyo and AstraZeneca announced that the European Commission (EC) has approved Datroway® (datopotamab deruxtecan)...
AstraZeneca’s Sone-Ve Delivers Phase III Survival Breakthrough
CAMBRIDGE, UK, July 27, 2026 AstraZeneca has announced positive high-level results from the global Phase III CLARITY-Gastric01 trial, demonstrating...
Advertisement
